Luiza Handschuh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Luiza Handschuh has a total of 203 co-authors. Here are the top co-authors by number of shared publications:
- Piotr Kozlowski
Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland
51 shared publications - Anna Philips
Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland
46 shared publications - Marcin Schmidt
Department of Biotechnology and Food Microbiology, Poznan University of Life Sciences, 60-627 Poznan, Poland
43 shared publications - Andrzej Mackiewicz
Department of Cancer Immunology, Poznan University of Medical Sciences, 61-866 Poznań, Poland
42 shared publications - Anna Samelak-Czajka
Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland
42 shared publications - Bernadeta Pietrzak
Department of Biotechnology and Food Microbiology, Poznan University of Life Sciences, 60-627 Poznan, Poland
42 shared publications
Latest Publications
- Open Access
- 11 September 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (17) , e71338
Integrative Long‐Read Multi‐Omics of a Patient With GPI Deficiency: A Molecular Case Study of a Candidate Dual‐Effect GPI Variant
The molecular determinants of phenotypic severity in red cell enzymopathies are often obscured by the disconnect between coding sequence variants and their regulatory landscapes. Here we present a single‐patient molecular case study that uses an integrative multi‐omic approach—combining short‐read WGS, PacBio HiFi long‐read sequencing, native CpG methylation profiling, and Iso‐Seq full‐length transcriptomics—to characterize a severe, transfusion‐dependent hemolytic anaemia. We identified a compound heterozygous state in the glucose‐6‐phosphate isomerase (GPI) gene, with no wild‐type allele present. One allele (Haplotype 1) carried a missense variant (p.His191Arg); the other (Haplotype 2) carried a distinct missense variant, c.1414C>T (p.Arg472Cys), previously reported as biochemically unstable. Long‐read phasing placed the two variants in trans. Allele‐resolved transcript counts showed a directionally consistent but statistically non‐significant trend toward higher expression of Haplotype 2 across two Iso‐Seq replicates. Notably, the c.1414C>T transition abolishes a local CpG dinucleotide; in a small number of haplotype‐2 reads spanning this position, the corresponding cytosine on the wild‐type/Haplotype‐1 background was methylated. We did not measure GPI protein abundance, enzymatic activity, or stability in this patient, and we do not establish that methylation at this site regulates GPI transcription. On the basis of these correlative observations in a single patient, we propose—as a hypothesis for future testing—that a coding variant might simultaneously perturb protein stability and disrupt a local epigenetic mark, and we outline the experiments required to test whether such a dual effect contributes to disease. This case illustrates the value of integrative long‐read multi‐omics for generating mechanistic hypotheses about variants of uncertain significance, while underscoring that causal claims require dedicated functional validation.
- 11 September 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (17) , e71338
Open AccessIntegrative Long‐Read Multi‐Omics of a Patient With GPI Deficiency: A Molecular Case Study of a Candidate Dual‐Effect GPI Variant
The molecular determinants of phenotypic severity in red cell enzymopathies are often obscured by the disconnect between coding sequence variants and their regulatory landscapes. Here we present a single‐patient molecular case study that uses an integrative multi‐omic approach—combining short‐read WGS, PacBio HiFi long‐read sequencing, native CpG methylation profiling, and Iso‐Seq full‐length transcriptomics—to characterize a severe, transfusion‐dependent hemolytic anaemia. We identified a compound heterozygous state in the glucose‐6‐phosphate isomerase (GPI) gene, with no wild‐type allele present. One allele (Haplotype 1) carried a missense variant (p.His191Arg); the other (Haplotype 2) carried a distinct missense variant, c.1414C>T (p.Arg472Cys), previously reported as biochemically unstable. Long‐read phasing placed the two variants in trans. Allele‐resolved transcript counts showed a directionally consistent but statistically non‐significant trend toward higher expression of Haplotype 2 across two Iso‐Seq replicates. Notably, the c.1414C>T transition abolishes a local CpG dinucleotide; in a small number of haplotype‐2 reads spanning this position, the corresponding cytosine on the wild‐type/Haplotype‐1 background was methylated. We did not measure GPI protein abundance, enzymatic activity, or stability in this patient, and we do not establish that methylation at this site regulates GPI transcription. On the basis of these correlative observations in a single patient, we propose—as a hypothesis for future testing—that a coding variant might simultaneously perturb protein stability and disrupt a local epigenetic mark, and we outline the experiments required to test whether such a dual effect contributes to disease. This case illustrates the value of integrative long‐read multi‐omics for generating mechanistic hypotheses about variants of uncertain significance, while underscoring that causal claims require dedicated functional validation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti–PD-1 Therapy
Supplementary Figure 10. Relative abundance of selected species in patients that exhibited benefits during anti-PD-1 treatment and patients who did not show benefits (CB vs. NB).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti–PD-1 Therapy
Supplementary Figure 10. Relative abundance of selected species in patients that exhibited benefits during anti-PD-1 treatment and patients who did not show benefits (CB vs. NB).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti–PD-1 Therapy
Supplementary Figure 3. Relative abundance of Candida glabrata in normal (18.5
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti–PD-1 Therapy
Supplementary Figure 3. Relative abundance of Candida glabrata in normal (18.5
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 11 from Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti–PD-1 Therapy
Supplementary Figure 11. Relative abundance of selected species in responders and non responders (R vs. NR).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 11 from Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti–PD-1 Therapy
Supplementary Figure 11. Relative abundance of selected species in responders and non responders (R vs. NR).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti–PD-1 Therapy
Supplementary Figure 5. The relative fungi abundance of melanoma and healthy samples at different taxonomical levels: (A) Phylum (B) Class (C) Order (D) Family.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti–PD-1 Therapy
Supplementary Figure 5. The relative fungi abundance of melanoma and healthy samples at different taxonomical levels: (A) Phylum (B) Class (C) Order (D) Family.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti–PD-1 Therapy
Supplementary Figure 7. Relative abundance of selected species during anti-PD-1 treatment.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti–PD-1 Therapy
Supplementary Figure 7. Relative abundance of selected species during anti-PD-1 treatment.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti–PD-1 Therapy
Supplementary Figure 6. Gut microbiota richness.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti–PD-1 Therapy
Supplementary Figure 6. Gut microbiota richness.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti–PD-1 Therapy
Supplementary Figure 2. (A) Shannon diversity of patients with normal (n=102) and elevated level of serum LDH (n=16). Kruskal–Wallis test was performed to compare groups, p1.5x, what corresponds to >375 U/L, n=16). Welch Two Sample t-test was performed to compare groups, padj<0.05 (FDR). Horizontal line shows median. Red dot shows mean. Dots represent individual samples.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti–PD-1 Therapy
Supplementary Figure 2. (A) Shannon diversity of patients with normal (n=102) and elevated level of serum LDH (n=16). Kruskal–Wallis test was performed to compare groups, p1.5x, what corresponds to >375 U/L, n=16). Welch Two Sample t-test was performed to compare groups, padj<0.05 (FDR). Horizontal line shows median. Red dot shows mean. Dots represent individual samples.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti–PD-1 Therapy
Supplementary Table 1. Melanoma patients and healthy controls data.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti–PD-1 Therapy
Supplementary Table 1. Melanoma patients and healthy controls data.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends and Tables 2-9 from Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti–PD-1 Therapy
Supplementary Figure Legends and Tables 2-9
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends and Tables 2-9 from Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti–PD-1 Therapy
Supplementary Figure Legends and Tables 2-9